Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-009-2 | CAS number: 112-84-5
Bioaccumulation: aquatic / sediment
Administrative data
Link to relevant study record(s)
Description of key information
Meylan et al. (1999) methodology updated with the Arnot and Gobas’ database (2008) uses different equations depending on the partition coefficient of the chemical. This QSAR is considered relevant for the estimation of the BCF of amides. The QSAR estimates that Erucamide is not a “B” substance. A worst case BCF based on no biotransformation estimates a BCF of 1893 L/Kg. All other estimates ore considerably lower: 659.9 estimated by Mehlan or less than 100 for 3 other QSARs.
Key value for chemical safety assessment
Additional information
Based on the different QSAR predictions, Meylan et al.(1999) methodology updated with the Arnot and Gobas’ database (2008) uses different equations depending on the partition coefficient of the chemical. The QSAR is considered relevant for the estimation of the BCF of amides. The in vitro study from Du Pont de Nemour (1997) indicated that there was no metabolite biotransformation in fish hepatocytes, but no information was provided on other mechanistic processes, such as chemical uptake from the water at the cell membrane surface and chemical elimination at the membrane surface. These processes and others (e.g. faecal egestion and growth dilution) are included in the Arnot-Gobas model and this QSAR estimates that Erucamide is not a “B” substance. As water solubility is extremely low (<1 µg/L) it is also possible that bioavailablity to the hepatocytes may not have been high enough in the test for the cells to absorb the substance and to demonstrate significant metabolism.
Equations from Arnot and Gobas would conclude that high bioaccumulation potential is likely if no biotransformation is assumed. But evidence from alkenes and acid surrogates show that metabolism should not be ignored for amides. In this case it can be concluded that Erucamide is not a “B” substance according to this QSAR.
Overall, Erucamide would not be a “B” substance in this assessment however a more pecise estimate of BCF cannot be provided. Due to technical difficulties it is not currently possible to perform a BCF study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
